Company news

Biotron Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited

October 3, 2022

Bit225 Covid-19 Human Study Commenced

September 13, 2022

BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited

August 23, 2022

Positive FDA guidance for COVID-19 clinical program

May 30, 2022

BIT225 effective against established SARS-CoV-2 in animals

May 2, 2022

Quarterly Cash Flow Report Appendix 4C

April 26, 2022

Quarterly Activities Report

April 26, 2022

$1.56M R&D Rebate Received

April 5, 2022

BIT225 Effectiveness Against COVID-19 in Animals

March 17, 2022

Quarterly Appendix 4C Cash Flow Report

January 27, 2022

Biotron drug effective against COVID-19 in animals

November 24, 2021

Commencement of two pivotal BIT225 clinical trials

November 1, 2021

Quarterly Cash Flow Report

October 27, 2021

Full Year Statutory Accounts and Preliminary Final Report

August 27, 2021

$1.4M R&D Tax Rebate

April 28, 2021

Appendix 4C - quarterly

April 28, 2021

Quarterly Cashflow Report

January 28, 2021

Biotron Compounds Show Activity Against SARS-CoV-2 Virus

September 6, 2020

Full Year Statutory Accounts

August 27, 2020

BIT225 Reverses HIV-Induced Immune Evasion

July 6, 2020

R&D Tax Refund Received

March 18, 2020

BIT225 restores immune function in HIV-1 infections

March 11, 2020

Biotron to Test its Compounds Against Coronavirus

February 5, 2020

Biotron Secures $5.1 Million Underwriting Agreement

November 8, 2019

Presentation to Investors

October 31, 2019

Appointment of International Advisory Board for BIT225

October 1, 2019

Presentation at BIO 2019

June 7, 2019

Presentation of BIT225-009 HIV-1 Phase 2 data

November 28, 2018

Response to ASX aware letter

October 30, 2018

Biotron Secures $4.7 Million Underwriting Agreement

October 16, 2018

$1.07 million R&D Tax Incentive Received

October 14, 2018

Significant Immunological Outcomes in BIT225 HIV-1 Trial

September 28, 2018

Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial

August 7, 2018

Response to ASX Appendix 4C Query

May 10, 2018

Biotron Compounds Demonstrate Activity Against HBV

November 15, 2017

$1.6 Million R&D Tax Incentive Received

November 1, 2017

BIT225 Phase 2 HIV-1 Clinical Trial Update

June 15, 2017

$1.6 Million R&D Tax Rebate Received

February 12, 2017

BIT225 Accelerates HIV-1 Virus Reduction

February 6, 2017

Zika Virus Program Update

August 22, 2016

Biotron compounds demonstrate activity against Zika virus

May 23, 2016

$1.5 Million R&D Tax Rebate

April 20, 2016

Trading halt

March 30, 2016

Phase 2 Hepatitis C Trial Success

March 17, 2016

BIT225 May have a broader role in limiting HIV-1 infection

February 18, 2016

Biotron compounds tested for activity against Zika virus

February 16, 2016

Interim HCV genotype 3 data from BIT225-008 study

February 11, 2016

Annual Report to Shareholders

February 10, 2016

← Newer news releases

Decks

The 5 newest of 101 decks. Every deck is listed under its year.